A Phase 3 interventional study of Vilanterol and Salmeterol Inhalation Powder in Asthma, sponsored by GlaxoSmithKline. Completed at 34 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-11-08.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing vilanterol in Asthma — none open to participants now, 2 under way, 2 of them phase 3. vilanterol · Asthma.
Among the 30 studies testing vilanterol in Asthma, this one is the 8th largest by enrollment, is one of 10 that started in 2010, is one of 14 in phase 3, and was the 8th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 30 studies testing vilanterol in Asthma is open now. The open studies under Asthma, anywhere →
vilanterol: first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 10 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 348 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 69 across the 30 interventional studies. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 30 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 66th largest by enrollment of the 238 interventional ones that give a count, is one of 34 that started in 2010, is one of 61 in phase 3, and was the 102nd registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing vilanterol in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing vilanterol in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a 12-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vilanterol inhalation powder once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
Drug: Vilanterol · Drug: Placebo Inhalation Powder Diskus
Placebo inhalation powder via NDPI once daily + Salmeterol inhalation powder twice daily for 12 weeks
Drug: Salmeterol Inhalation Powder · Drug: Placebo Inhalation Powder NDPI
Placebo inhalation powder via NDPI once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
Drug: Placebo Inhalation Powder NDPI · Drug: Placebo Inhalation Powder Diskus
Vilanterol inhalation powder inhaled orally once daily for 12 weeks
Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
Placebo inhalation powder inhaled orally twice daily for 12 weeks
Change From Baseline in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at Week 12
FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The weighted mean is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, at Week 12. The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline is calculated as the weighted mean 0-24 hour FEV1 (Liters) at Week 12 minus the Baseline value. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment.
Time frame: Baseline and Week 12
Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period
The time span during which the participants did not have to take any rescue bronchodilator (medication intended to relieve symptoms immediately) was considered to be a rescue-free period. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
Time frame: Baseline and Weeks 1-12
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period
Participants who were symptom free for 24-hour periods during the12-week treatment period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
Time frame: Baseline and Weeks 1-12
Change From Baseline in Individual Serial FEV1 Assessments at the End of the 12-week Treatment Period, Including the 12-hour and 24-hour Time Points
FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The individual serial FEV1 is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 3, 5, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, relatively, on Treatment Day 84 (Week 12). The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline was calculated as the value of the individual serial FEV1 taken at Week 12 minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment. Analysis was performed separately for each planned time point.
Time frame: Baseline and Week 12
Change From Baseline in Daily Trough (Pre-dose and Pre-rescue Bronchodilator) PM (Evening) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily PM PEF prior to randomization. Change from Baseline in trough PM PEF was calculated as the averaged value of all daily PM PEF for Week 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
Time frame: Baseline and Weeks 1-12
Change From Baseline in Daily AM (Morning) PEF Averaged Over the 12-week Treatment Period
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily AM PEF prior to randomization. Change from Baseline in trough AM PEF was calculated as the averaged value of all daily AM PEF for Weeks 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
Time frame: Baseline and Weeks 1-12
Number of Participants With the Indicated Time to an Increase of >=12% and >=200 Milliliters (mL) Above Baseline in FEV1 on Day 1 and Day 84 (0-2 Hours)
The number of participants with a \>=12% and \>=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated on Day 1 and Week 12 for the time to a \>=12% increase from Baseline (at the 5 minutes (min), 15 min, 30 min, 1hour (hr), and 2 hr nominal time points. Participants who did not achieve a \>=12% and \>=200 mL increase from Baseline in FEV1 over this time period were considered censored.
Time frame: Day 1 and Week 12
Number of Participants With the Indicated Global Assessment of Change Questionnaire Responses at the End of Week 4 and Week 12
At the end of Week 4 and Week 12, the Global Assessment of Change Questionnaire, which assesses changes in asthma symptoms and rescue medication use, was completed by participants using the following scale: asthma symptom (AS) change: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse; rescue medication use (RMU): much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often.
Time frame: Week 4 and Week 12
347 participants (par.) were randomized to treatment; all 347 were included in the Intent-to-Treat (ITT) Population. One par. was not randomized but received treatment in error. This par. was not included in the ITT Population and is thus not captured in the Participant Flow module. This par. is categorized as being enrolled in the study (n=348).
| Milestone | Placebo | Vilanteral 25 µg OD | Salmeterol 50 µg BID |
|---|---|---|---|
| Started | 116 | 115 | 116 |
| Completed | 99 | 101 | 98 |
| Not completed | 17 | 14 | 18 |
| Withdrew: Adverse event | 3 | 1 | 1 |
| Withdrew: Lack of efficacy | 8 | 9 | 9 |
| Withdrew: Protocol violation | 2 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 2 |
| Withdrew: Investigator discretion | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 3 | 0 | 5 |
FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The weighted mean is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, at Week 12. The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline is calculated as the weighted mean 0-24 hour FEV1 (Liters) at Week 12 minus the Baseline value. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment.
| Liters | Placebo | Vilanteral 25 µg OD | Salmeterol 50 µg BID |
|---|---|---|---|
| Change From Baseline in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at Week 12 | 0.289 ± 0.0429 | 0.359 ± 0.0416 | 0.283 ± 0.0419 |
The time span during which the participants did not have to take any rescue bronchodilator (medication intended to relieve symptoms immediately) was considered to be a rescue-free period. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
| Percentage of rescue-free 24-hr periods | Placebo | Vilanteral 25 µg OD | Salmeterol 50 µg BID |
|---|---|---|---|
| Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period | 14.6 ± 2.71 | 21.7 ± 2.68 | 22.9 ± 2.72 |
Participants who were symptom free for 24-hour periods during the12-week treatment period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
| Percentage of symptom-free 24-hr periods | Placebo | Vilanteral 25 µg OD | Salmeterol 50 µg BID |
|---|---|---|---|
| Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period | 12.7 ± 2.58 | 19.4 ± 2.55 | 19.5 ± 2.59 |
FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The individual serial FEV1 is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 3, 5, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, relatively, on Treatment Day 84 (Week 12). The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline was calculated as the value of the individual serial FEV1 taken at Week 12 minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment. Analysis was performed separately for each planned time point.
| Liters | Placebo | Vilanteral 25 µg OD | Salmeterol 50 µg BID |
|---|---|---|---|
| Predose, n=97,104,101 | 0.302 ± 0.0446 | 0.272 ± 0.0430 | 0.233 ± 0.0437 |
| 5 min, n=95,100,98 | 0.313 ± 0.0450 | 0.301 ± 0.0438 | 0.214 ± 0.0443 |
| 15 min, n=96, 101, 99 | 0.308 ± 0.0450 | 0.324 ± 0.0439 | 0.257 ± 0.0444 |
| 30 min, n=,96,101,100 | 0.322 ± 0.0443 | 0.344 ± 0.0432 | 0.272 ± 0.0435 |
| 60 min, n=96, 101, 100 | 0.336 ± 0.0445 | 0.352 ± 0.0433 | 0.296 ± 0.0437 |
| 2 hours, n=96, 100, 99 | 0.313 ± 0.0455 | 0.369 ± 0.0446 | 0.335 ± 0.0449 |
| 3 hours, n=96, 101, 100 | 0.304 ± 0.0455 | 0.374 ± 0.0444 | 0.316 ± 0.0447 |
| 4 hours, n=96, 101, 100 | 0.311 ± 0.0450 | 0.359 ± 0.0438 | 0.293 ± 0.0441 |
| 5 hours, n=96, 100, 100 | 0.292 ± 0.0455 | 0.368 ± 0.0445 | 0.279 ± 0.0447 |
| 11 hours, n=94, 99, 96 | 0.195 ± 0.0508 | 0.312 ± 0.0494 | 0.179 ± 0.0505 |
| 12 hours, n=93,98,95 | 0.250 ± 0.0477 | 0.341 ± 0.0465 | 0.217 ± 0.0473 |
| 12.5 hours, n=96, 97, 98 | 0.270 ± 0.0446 | 0.337 ± 0.0444 | 0.282 ± 0.0443 |
| 13 hours, 96, 98, 100 | 0.312 ± 0.0448 | 0.341 ± 0.0442 | 0.304 ± 0.0440 |
| 14 hours, n=95, 99, 99 | 0.341 ± 0.0445 | 0.401 ± 0.0436 | 0.359 ± 0.0437 |
| 16 hours, n=95, 98, 97 | 0.364 ± 0.0464 | 0.371 ± 0.0457 | 0.357 ± 0.0461 |
| 20 hours, n= 94, 101, 99 | 0.318 ± 0.0485 | 0.371 ± 0.0467 | 0.296 ± 0.0473 |
| 23 hours, 94, 101, 99 | 0.310 ± 0.0456 | 0.345 ± 0.0440 | 0.271 ± 0.0446 |
| 24 hours, n= 95, 101, 100 | 0.301 ± 0.0445 | 0.330 ± 0.0432 | 0.275 ± 0.0435 |
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily PM PEF prior to randomization. Change from Baseline in trough PM PEF was calculated as the averaged value of all daily PM PEF for Week 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
| Liters per minute (L/min) | Placebo | Vilanteral 25 µg OD | Salmeterol 50 µg BID |
|---|---|---|---|
| Change From Baseline in Daily Trough (Pre-dose and Pre-rescue Bronchodilator) PM (Evening) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period | 11.0 ± 3.15 | 24.9 ± 3.14 | 18.8 ± 3.17 |
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily AM PEF prior to randomization. Change from Baseline in trough AM PEF was calculated as the averaged value of all daily AM PEF for Weeks 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
| Liters per minute (L/min) | Placebo | Vilanteral 25 µg OD | Salmeterol 50 µg BID |
|---|---|---|---|
| Change From Baseline in Daily AM (Morning) PEF Averaged Over the 12-week Treatment Period | 14.2 ± 3.25 | 28.0 ± 3.24 | 23.6 ± 3.27 |
The number of participants with a \>=12% and \>=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated on Day 1 and Week 12 for the time to a \>=12% increase from Baseline (at the 5 minutes (min), 15 min, 30 min, 1hour (hr), and 2 hr nominal time points. Participants who did not achieve a \>=12% and \>=200 mL increase from Baseline in FEV1 over this time period were considered censored.
| Participants | Placebo | Vilanteral 25 µg OD | Salmeterol 50 µg BID |
|---|---|---|---|
| Day 1, 5 min, n=113, 115, 116 | 23 | 33 | 18 |
| Day 1, 15 min, n=113, 115, 116 | 2 | 11 | 11 |
| Day 1, 30 min, n=113, 115, 1116 | 3 | 8 | 13 |
| Day 1, 1 hr, n=113, 115, 116 | 3 | 7 | 6 |
| Day 1, 2 hr, n=113, 115, 116 | 5 | 6 | 11 |
| Day 1, Censored, n=113, 115, 116 | 77 | 50 | 57 |
| Week 12, 5 min, n=96, 101, 100 | 39 | 42 | 30 |
| Week 12, 15 min, n=96, 101, 100 | 6 | 2 | 7 |
| Week 12, 30 min, n=96, 101, 100 | 2 | 2 | 8 |
| Week 12, 1 hr, n=96, 101, 100 | 1 | 4 | 5 |
| Week 12, 2 hr, n=96, 101, 100 | 3 | 7 | 4 |
| Week 12, Censored, n=96, 101, 100 | 45 | 44 | 46 |
At the end of Week 4 and Week 12, the Global Assessment of Change Questionnaire, which assesses changes in asthma symptoms and rescue medication use, was completed by participants using the following scale: asthma symptom (AS) change: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse; rescue medication use (RMU): much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often.
| Participants | Placebo | Vilanteral 25 µg OD | Salmeterol 50 µg BID |
|---|---|---|---|
| Week 4, AS: Much better, n=110, 109, 110 | 25 | 37 | 34 |
| Week 4, AS: Somewhat better, n=110, 109, 110 | 35 | 43 | 34 |
| Week 4, AS: A little better, n=110, 109, 110 | 24 | 14 | 21 |
| Week 4, AS: The same, n=110, 109, 110 | 17 | 13 | 16 |
| Week 4, AS: A little worse, n=110, 109, 110 | 6 | 1 | 3 |
| Week 4, AS: Somewhat worse, n=110, 109, 110 | 2 | 0 | 2 |
| Week 4, AS: Much worse, n=110, 109, 110 | 1 | 1 | 0 |
| Week 4, RMU: Much less often, n=110, 109, 110 | 18 | 33 | 28 |
| Week 4, RMU: Somewhat less often, n=110, 109, 110 | 40 | 31 | 36 |
| Week 4, RMU: A little less often, n=110, 109, 110 | 18 | 23 | 20 |
| Week 4, RMU: The same, n=110, 109, 110 | 26 | 18 | 17 |
| Week 4, RMU: A little more often, n=110, 109, 110 | 4 | 3 | 7 |
| Week 4, RMU: Somewhat more often, n=110, 109, 110 | 2 | 0 | 2 |
| Week 4, RMU: Much more often, n=110, 109, 110 | 2 | 1 | 0 |
| Week 12, AS: Much better, n=100, 105, 101 | 31 | 52 | 35 |
| Week 12, AS: Somewhat better, n=100, 105, 101 | 35 | 31 | 34 |
| Week 12, AS: A little better, n=100, 105, 101 | 13 | 9 | 16 |
| Week 12, AS: The same, n=100, 105, 101 | 12 | 9 | 11 |
| Week 12, AS: A little worse, n=100, 105, 101 | 4 | 2 | 4 |
| Week 12, AS: Somewhat worse, n=100, 105, 101 | 4 | 1 | 1 |
| Week 12, AS: Much worse, n=100, 105, 101 | 1 | 1 | 0 |
| Week 12, RMU: Much less often, n=100, 105, 101 | 25 | 40 | 32 |
| Week 12, RMU: Somewhat less often, n=100, 105, 101 | 31 | 32 | 29 |
| Week 12, RMU: A little less often, n=100, 105, 101 | 13 | 16 | 13 |
| Week 12, RMU: The same, n=100, 105, 101 | 23 | 11 | 21 |
| Week 12, RMU: A little more often, n=100, 105, 101 | 2 | 5 | 4 |
| Week 12, RMU: Somewhat more often, n=100, 105, 101 | 4 | 0 | 2 |
| Week 12, RMU: Much more often, n=100, 105, 101 | 2 | 1 | 0 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/116 (0.9%) | 26/116 (22.4%) |
| Vilanteral 25 µg OD | — | 1/115 (0.9%) | 26/115 (22.6%) |
| Salmeterol 50 µg BID | — | 0/116 (0%) | 21/116 (18.1%) |
| Event | Placebo | Vilanteral 25 µg OD | Salmeterol 50 µg BID |
|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/116 | 1/115 | 0/116 |
| Sudden deathGeneral disorders | 1/116 | 0/115 | 0/116 |
| Event | Placebo | Vilanteral 25 µg OD | Salmeterol 50 µg BID |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 12/116 | 9/115 | 7/116 |
| HeadacheNervous system disorders | 5/116 | 10/115 | 9/116 |
| Upper respiratory tract infectionInfections and infestations | 8/116 | 2/115 | 2/116 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 7/116 | 6/115 | 2/116 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/116 | 0/115 | 5/116 |
| PyrexiaGeneral disorders | 0/116 | 4/115 | 1/116 |
| Age, Continuous(Years) | Placebo | Vilanteral 25 µg OD | Salmeterol 50 µg BID | Total |
|---|---|---|---|---|
| Mean | 41.7 ± 16.64 | 41.0 ± 17.81 | 41.1 ± 16.84 | 41.3 ± 17.06 |
| Sex: Female, Male(Participants) | Placebo | Vilanteral 25 µg OD | Salmeterol 50 µg BID | Total |
|---|---|---|---|---|
| Female | 59 | 68 | 77 | 204 |
| Male | 57 | 47 | 39 | 143 |
| Race/Ethnicity, Customized(Participants) | Placebo | Vilanteral 25 µg OD | Salmeterol 50 µg BID | Total |
|---|---|---|---|---|
| African American/African Heritage | 11 | 5 | 6 | 22 |
| American Indian or Alaska Native | 37 | 44 | 41 | 122 |
| Japanese/East Asian Heritage | 0 | 0 | 1 | 1 |
| White | 68 | 66 | 68 | 202 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Sep 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 2 years after primary completion. A results delay was requested in Jul 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vilanterol